Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025)
Immatics' (IMTX) quarterly Total Non-Current Liabilities came in at $41.0 million in Q4 2025, down 28.03% year-on-year from $57.0 million in Q4 2024, and down 11.47% quarter-over-quarter from $46.3 million in Q3 2025.
Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Immatics has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $41.0 million for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $41.0 million, down 28.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $41.0 million (down 28.03% YoY), and the FY2025 annual result was $39.8 million, down 30.15% from the prior year.
- Total Non-Current Liabilities came in at $41.0 million for Q4 2025 at Immatics, down from $46.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $146.1 million in Q4 2023 to a low of $41.0 million in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $78.3 million (2021), against an average of $83.3 million.
- Across the five-year window, Total Non-Current Liabilities soared 76.84% in 2022 and plunged 61.01% in 2024, its largest moves.
- Immatics' Total Non-Current Liabilities stood at $63.4 million in 2021, then soared by 57.69% to $100.0 million in 2022, then soared by 46.11% to $146.1 million in 2023, then plunged by 61.01% to $57.0 million in 2024, then slipped by 28.03% to $41.0 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $41.0 million (Q4 2025), $46.3 million (Q3 2025), and $51.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 41.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.00 Mn |
| Sep 30, 2025 | 46.32 Mn |
| Jun 30, 2025 | 51.48 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 56.97 Mn |
| Sep 30, 2024 | 75.95 Mn |
| Jun 30, 2024 | 103.55 Mn |
| Mar 31, 2024 | 119.38 Mn |
| Dec 31, 2023 | 146.11 Mn |
| Sep 30, 2023 | 74.62 Mn |
| Jun 30, 2023 | 73.69 Mn |
| Mar 31, 2023 | 83.53 Mn |
| Dec 31, 2022 | 100.00 Mn |
| Sep 30, 2022 | 118.10 Mn |
| Jun 30, 2022 | 138.04 Mn |
| Mar 31, 2022 | 83.44 Mn |
| Dec 31, 2021 | 63.42 Mn |
| Sep 30, 2021 | 66.78 Mn |
| Jun 30, 2021 | 80.61 Mn |
| Mar 31, 2021 | 91.77 Mn |